About The Study: The PROTECTED transcatheter aortic valve replacement (TAVR) trial could not show that the use of cerebral embolic protection (CEP) had a significant effect on the incidence of periprocedural stroke during TAVR. Although there was no significant interaction by geographic region, this exploratory post hoc analysis suggests a trend toward greater stroke reduction in the U.S. cohort but not in the outside the U.S. cohort. These findings are hypothesis generating, and further research is needed to determine if regional differences in patient characteristics or procedural practices affect CEP efficacy.
Corresponding Author: To contact the corresponding author, Raj R. Makkar, MD, email raj.makkar@cshs.org .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamacardio.2024.4278)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.4278?guestAccessKey=323860f8-c29c-4d58-ad6f-728382ca987a&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102924
JAMA Cardiology